Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plusdidanosine combination therapy
Autore:
Pellegrin, I; Izopet, J; Reynes, J; Denayrolles, M; Montes, B; Pellegrin, JL; Massip, P; Puel, J; Fleury, H; Segondy, M;
Indirizzi:
Bordeaux Univ Hosp, Dept Virol, Bordeaux, France Bordeaux Univ Hosp Bordeaux France v Hosp, Dept Virol, Bordeaux, France Bordeaux Univ Hosp, Dept Infect Dis, Bordeaux, France Bordeaux Univ Hosp Bordeaux France p, Dept Infect Dis, Bordeaux, France Toulouse Univ Hosp, Dept Virol, Toulouse, France Toulouse Univ Hosp Toulouse France v Hosp, Dept Virol, Toulouse, France Toulouse Univ Hosp, Dept Infect Dis, Toulouse, France Toulouse Univ Hosp Toulouse France p, Dept Infect Dis, Toulouse, France Montpellier Univ Hosp, Dept Virol, Montpellier, France Montpellier Univ Hosp Montpellier France ept Virol, Montpellier, France Montpellier Univ Hosp, Dept Infect Dis, Montpellier, France Montpellier Univ Hosp Montpellier France nfect Dis, Montpellier, France
Titolo Testata:
AIDS
fascicolo: 13, volume: 13, anno: 1999,
pagine: 1705 - 1709
SICI:
0269-9370(19990910)13:13<1705:EOZAMM>2.0.ZU;2-I
Fonte:
ISI
Lingua:
ENG
Soggetto:
VIRUS TYPE-1 VARIANTS; DRUG-RESISTANCE; SUSCEPTIBILITY; MONOTHERAPY; INHIBITORS; SELECTION;
Keywords:
zidovudine; stavudine; lamivudinel; HIV-1; reverse transcriptase; resistance mutation;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
16
Recensione:
Indirizzi per estratti:
Indirizzo: Pellegrin, I Hop Pellegrin, Virol Lab, Pl Amelie Raba Leon, F-33076 Bordeaux, France Hop Pellegrin Pl Amelie Raba Leon Bordeaux France F-33076 ce
Citazione:
I. Pellegrin et al., "Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plusdidanosine combination therapy", AIDS, 13(13), 1999, pp. 1705-1709

Abstract

Objective: Assessment of genotypic changes in the reverse transcriptase gene of HIV-1 occurring in antiretroviral naive patients treated by stavudineplus didanosine combination therapy. Methods: Sequence analysis (codons 1-230) was-performed after amplification of the reverse transcriptase gene from plasma samples collected at baseline and at the end of treatment from 39 previously treatment-naive patients treated for 24-48 weeks. Results: At baseline, mutations associated with zidovudine resistance weredetected in plasma from two patients: Asp67Asn/Lys219Gln and Leu210Trp. Among the 39 subjects, 18 (46%) developed mutations: one developed the Val75Thr/Ala mutation, four (10%) developed a Gln151Met multidrug-resistance mutation (MDR), associated in one of them with the Phe77Leu and the Phe116Tyr MDR mutations and 14 (36%) developed one or more zidovudine-specific mutations (Met41Leu, Asp67Asn, Lys70Arg, Leu210Trp, Thr215Tyr/Phe). The development of a Met41Leu zidovudine-specific mutation was associated with the development of a Gln151Met mutation in one patient. Other reverse transcriptase mutations known to confer resistance to nucleoside analogues were not detected. At inclusion, there was no statistical difference in HIV-1 load betweenpatients who developed resistance mutations and those who did not. RNA HIV-1 load decrease was higher (P = 0.05) in patients who maintained a wild-type reverse transcriptase genotype (-2.22 log(10) copies/ml) than in patients who developed resistance mutations (-1.14 log(10) copies/ml). Conclusion: Stavudine/didanosine combination therapy is associated with emergence of zidovudine-related resistance or MDR mutations in naive patients. These findings should be considered when optimizing salvage therapy for patients who have received a treatment including stavudine/didanosine combination. (C) 1999 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/11/20 alle ore 04:43:28